We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Microbiologics Introduces SARS-CoV-2 Synthetic RNA for COVID-19 Research

By HospiMedica International staff writers
Posted on 18 Mar 2020
Microbiologics, Inc. More...
(Saint Cloud, MN, USA) has prepared synthetic RNA for SARS-CoV-2 to assist in the efforts to monitor the spread of COVID-19.

Microbiologics, a biological products and services provider, partners with healthcare and life science laboratories, manufacturers and suppliers across the world to co-create and provide biological control materials, assay services and consulting for microbiology, molecular diagnostics and virology.

The SARS-CoV-2 material is a 1044 nucleotide RNA specific for the SARS-CoV-2 N (nucleocapsid) gene. It contains all three markers (N1, N2 and N3) detected by the CDC Real-Time RT PCR Panel for Detection of 2019 Novel Coronavirus. The RNA material assists in the development of diagnostic assays and the evaluation of the performance of nucleic acid tests for determination of the presence of SARS-COV-2.

The SARS-CoV-2 RNA is available in two different concentrations: 1 x 106 and 1 x 109 genome copies per tube. An IVD version of the product will be added to the Helix EliteTM line from Microbiologics and will be available in the coming weeks.

“We are engaged with our partners and researchers to offer Microbiologics’ virology and molecular biology capabilities to accelerate diagnostics and therapeutic research,” said Brian Beck, Microbiologics’ VP of R&D. “This new RNA material from Microbiologics mimics the viral nucleic acid and provides the exact targets specified by the CDC.”

“In order to effectively respond to the COVID-19 outbreak, scientists need to have confidence in their diagnostic tools to provide rapid, accurate results,” added Beck. “This SARS-CoV-2 material is a critical step forward in our global response against this new strain of coronavirus.”

Related Links:
Microbiologics, Inc.


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.